In the present study we confirmed the negative prognostic value of TP53 exon 8 mutation in an independent cohort of EGFR-mutated NSCLC treated with both first and second generation TKIs in the first line setting. This evidence concerns the gene TP53 and non-small cell lung carcinoma.